Detailed Narrative
Innovation-Driven Growth Strategy
IDEXX's 2025 performance was driven by its innovation strategy, including successful scaling of new platforms like inVue Dx, Cancer Dx, Vello, and Catalyst Cortisol. These solutions provided valuable insights and productivity lifts for customers, reinforcing the company's leadership in diagnostics and software. The strategy focuses on customer-centric innovation and solutions deeply embedded in veterinary workflows, contributing to strong recurring revenue.
Commercial Expansion and Customer Engagement
The company completed a targeted expansion of its commercial footprint in Q4 FY25 in key international regions (Germany, UK, Australia) and the U.S. This expansion reduced the number of accounts per representative, enabling more frequent and higher-quality interactions, which historically leads to increased utilization and customer satisfaction. Customer retention in Global CAG Diagnostics remains in the high 90s, underscoring the value of IDEXX solutions.
Aging Pet Population and Diagnostic Frequency
The deepening human-animal bond and commitment to high-standard care, especially for aging pets, is a key driver. Early signs of aging pets (canines 5+ years old) showed solid visit growth for non-wellness visits for a second consecutive quarter. Diagnostic frequency, the percentage of visits including diagnostic testing, expanded in Q4, highlighting structural demand for advanced diagnostics and its role in driving broader veterinary care.
inVue Dx Transformational Impact
The inVue Dx platform has been one of IDEXX's most successful product launches, with nearly 6,400 placements in 2025. Its controlled launch of fine needle aspirate (FNA) capability in December for mast cell tumor detection is viewed as a significant platform expansion. FNA automates key steps and applies AI-powered analysis, providing results within minutes, enhancing clinical confidence for cancer screening and diagnosis.
Catalyst Platform Expansion
The Catalyst platform continues to deliver value through disciplined menu expansions, including Catalyst Pancreatic Lipase (broad uptake in 2025) and Catalyst Cortisol (launched Q3 FY25). These additions enable faster, more informed decisions at the point of care. Over 50% of North American Catalyst users adopted the Pancreatic Lipase Test in the first 12 months, demonstrating rapid uptake across the approximately 78,000 global Catalyst installed base.
Software Ecosystem as a Growth Driver
IDEXX's software ecosystem, including cloud-based PIMS (ezyVet and Neo) and pet owner engagement tools like Vello, is a significant growth driver. Cloud-based PIMS saw double-digit installed base growth, particularly among multi-location practices. Vello users grew over 40% quarter-over-quarter and nearly tripled year-over-year, leading to fewer no-shows, more clinical visits, and increased diagnostics usage in practices that adopt it.
Cancer Dx Panel Expansion
The IDEXX Cancer Dx panel is expanding to include canine mast cell tumor detection, expected mid-2026 in North America, building on the successful commercialization of canine lymphoma. The lymphoma test has shown potential for early detection (up to 8 months prior to clinical manifestation) and monitoring remission during chemotherapy, with an addressable opportunity of approximately 130,000 tests per year in North America for monitoring alone.